Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The ...

The effort is designed to raise awareness of RMS — and which is the most common form of MS — as well as the treatment option of Mavenclad (cladribine) tablets, which are produced by the healthcare ...

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by Merck. It has been approved by the National Institute for Health and Care ...

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by Merck. It has been approved by the National Institute for Health and Care ...

Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad, reducing their need for clinic visits. New guidance (PDF ...

Europe’s CHMP top scientific committee gave a positive opinion for approval to cladribine, with the proposed trade name Mavenclad, for relapsing forms of MS with high disease activity.

Each of us has enough DNA to reach from here to the sun and back, more than 300 times. How is all of that DNA packaged so tightly into chromosomes and squeezed into a tiny nucleus? Histones are a ...

Zeit Aktuelle Nachrichten Do Weitere Übernahmen erwartet - Bayer, BioNxt Solutions, Merck KGaA Die aggressive Zollpolitik der neuen US-Administration mit US-Präsident Trump hat einige ...

Merck KGaA (TG:MRK) cut its growth forecast for its healthcare division, which includes multiple sclerosis drug Mavenclad and cancer treatment Bavencio. The company also lowered its growth target ...